Linaclotide

Linzess

Guanylate Cyclase-C Agonist

NADAC/unit $9.0216

No Shortage Tier 1: 53.8% PA Req: 0.9%

LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older • chronic idiopathic constipation (CIC) in ....

vs. brand Linzess: Generic saves up to 10% per unit

Covered Lives

Generic Manufacturers

ABBVIE INC

Explore in the Ecosystem

rxsaver.aiCompare prices for Linaclotide drfinder.aiFind doctors who prescribe Linaclotide rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Linaclotide

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.